Oncolytics Biotech Inc. (ONCY)

NASDAQ: ONCY · Real-Time Price · USD
0.6000
-0.0142 (-2.31%)
At close: Mar 28, 2025, 4:00 PM
0.5968
-0.0032 (-0.54%)
After-hours: Mar 28, 2025, 7:55 PM EDT
-2.31%
Market Cap 51.41M
Revenue (ttm) n/a
Net Income (ttm) -22.04M
Shares Out 86.42M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 223,000
Open 0.6150
Previous Close 0.6142
Day's Range 0.5900 - 0.6250
52-Week Range 0.5800 - 1.5300
Beta 1.49
Analysts Strong Buy
Price Target 4.00 (+566.67%)
Earnings Date Mar 7, 2025

About ONCY

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelare... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 8, 1999
Employees 28
Stock Exchange NASDAQ
Ticker Symbol ONCY
Full Company Profile

Financial Performance

Financial numbers in CAD Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ONCY stock is "Strong Buy." The 12-month stock price forecast is $4.0, which is an increase of 566.67% from the latest price.

Price Target
$4.0
(566.67% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2024 Results Conference Call March 7, 2025 8:30 AM ET Company Participants Jon Patton - Director of Investor Relations and Communications Wayne Pisano - Chair...

23 days ago - Seeking Alpha

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancreatic and anal carcinoma support con...

23 days ago - PRNewsWire

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Feb. 25, 2025 /PRNewswire/ --  Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC), a l...

4 weeks ago - PRNewsWire

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Regulatory progress in pancreatic cancer and recent clinical data presentations in two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, highlight pelareorep's potential...

5 weeks ago - PRNewsWire

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, demonstrate the potential of pelareorep across very different tumor typ...

5 weeks ago - PRNewsWire

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

SAN DIEGO and CALGARY, AB , Feb. 14, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announc...

6 weeks ago - PRNewsWire

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Search for Chief Executive Officer to commence immediately SAN DIEGO  and  CALGARY, AB , Feb. 7, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage compa...

7 weeks ago - PRNewsWire

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer patients Pelareorep-based therapy demonstrates strong safety profile with new chem...

2 months ago - PRNewsWire

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

New pancreatic cancer cohort moves forward with full enrollment of 30 patients in Stage 1 SAN DIEGO and CALGARY, AB , Jan. 15, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), ...

2 months ago - PRNewsWire

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

Promising BRACELET-1 results in HR+/HER2- metastatic breast cancer lay the foundation for potential registration-enabling study and accelerated approval Advancing gastrointestinal cancer pipeline unde...

3 months ago - PRNewsWire

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

SAN DIEGO  and CALGARY, AB , Dec. 18, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announ...

3 months ago - PRNewsWire

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort

Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without atezolizumab The study will begin with ...

4 months ago - PRNewsWire

Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript

Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript

4 months ago - Seeking Alpha

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study Upcoming GOB...

4 months ago - PRNewsWire

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

Conference call and webcast to take place on Tuesday, November 12, 2024, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Nov. 11, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a...

4 months ago - PRNewsWire

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

Recent clinical efficacy results from the BRACELET-1 trial in HR+/HER2- breast cancer pave the way for a clinical study designed to support an accelerated approval Key milestones in gastrointestinal c...

6 months ago - PRNewsWire

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study Together, these two studies support the compelling potential of pelareorep-based co...

6 months ago - PRNewsWire

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

SAN DIEGO and CALGARY, AB , Sept. 6, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announc...

7 months ago - PRNewsWire

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference

SAN DIEGO and CALGARY, AB , Aug. 2, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announce...

8 months ago - PRNewsWire

Oncolytics Biotech Inc. (ONCY) Q2 2024 Earnings Call Transcript

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q2 2024 Results Conference Call August 1, 2024 4:30 PM ET Company Participants Jon Patton - Director of Investor Relations and Communication Wayne Pisano - Chair...

8 months ago - Seeking Alpha

Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights

Received productive feedback from Type C meeting with the FDA for the planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer On track to report overall survival resul...

8 months ago - PRNewsWire

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights

Conference call and webcast to take place on Thursday, August 1, 2024, at 4:30 p.m. ET SAN DIEGO, Calif.

8 months ago - PRNewsWire

Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report overall survival results from the randomized HR+/HER2- ...

9 months ago - PRNewsWire

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence

Wayne Pisano, Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast cancer study continues to be expected in H2 2024 Pelareorep combination ther...

9 months ago - PRNewsWire

Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer

Demonstrating pelareorep's synergy with modified FOLFIRINOX +/- atezolizumab in pancreatic cancer could expand the number of patients it may benefit Funding for the study comes from the US$5 million T...

10 months ago - PRNewsWire